Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Approves New Drug for Parkinson’s Disease


Parkinson's Disease

The drug is designed to complement levodopa/carbidopa during periods of decreased medication effectiveness and increased symptom severity, known as an “off” episode.

Share this!

March 23, 2017 | by Sarah Hand, M.Sc.

Newron Pharmaceuticals’ Xadago (safinamide) has been approved by the US Food and Drug Administration (FDA) as an add-on medication for patients with Parkinson’s disease. The drug is designed to complement levodopa/carbidopa during periods of decreased medication effectiveness and increased symptom severity, known as an “off” episode.

“Parkinson's is a relentless disease without a cure,” said Dr. Eric Bastings, deputy director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. “We are committed to helping make additional treatments for Parkinson's disease available to patients.”

The FDA’s decision to approve the treatment was informed by a clinical trial of Xadago involving 645 patients. All patients in the trial were taking levodopa, however they were also experiencing an “off” time with an increase in symptoms such as tremor and difficulty walking.

Patients in the trial treated with Xadago showed a reduction of Parkinson’s symptoms during their “on” time, and a reduction in the duration of “off” time, compared to a placebo. An additional clinical trial involving 549 participants, showed similar results in terms of more productive “on” times with better scores on tests of motor function.

According to statistics from the National Institutes of Health (NIH), around 50,000 people in the US are diagnosed with Parkinson’s disease every year. Currently, approximately 1 million Americans suffer from the degenerative disorder.

The disease results in the death of dopamine-producing neurons in the brain. Dopamine is involved in transmitting signals throughout the brain, and allowing the muscles to move in a controlled and coordinated manner.

Levodopa is a first-line treatment for the management of Parkinson’s disease symptoms. It is converted into dopamine in the body, and acts as a replacement for the natural dopamine lost due to cell death.

Symptoms of Parkinson’s disease generally do not develop until age 60, although some patients experience earlier-onset. The cause of Parkinson’s disease is unknown, and there is no cure for the neurological disorder.

Keywords: FDA, Drug Approvals, Parkinson's Disease


Share this with your colleagues!

Samsung Bioepis and Takeda to Co-Develop Novel Biologic Drugs

August 22, 2017 - Biosimilars drugmaker Samsung Bioepis has joined forces with Takeda Pharmaceutical to develop biologic therapies in novel disease areas.

Featured In: Biotech News

Improving Administration of Blood Thinner Drugs through an Online Course for Nurses

August 22, 2017 - Patients’ refusal of blood thinners can influence a nurse’s decision to administer the drugs, but an online educational program could help to address this issue.

Featured In: Life Science News

Exploring the FDA’s Accelerated Approval Pathway

August 21, 2017 - Investigational new drugs that could fill an unmet medical need are sometimes granted “Accelerated Approval” by the US Food and Drug Administration (FDA) in an effort to make these medicines available to the patients who need them.

Featured In: Pharmaceutical News


One Patient’s Perspective on Clinical Trials


Planning and Conducting Trials of the Latest Immunotherapies

ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation

Medical Devices: Reviewing Regulatory Changes in the US and EU

Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.